A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms PIONEER6
- Sponsors Novo Nordisk
- 13 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2017 Status changed from not yet recruiting to recruiting.
- 28 Oct 2016 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.